NCT06963905 - Saci Nivo Rela for TNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions

Metastatic Triple-negative Breast Cancer

Interventions

DRUG

Relatlimab FDC + Nivolumab

Relatlimab: 360 IV Q3W (Dose level 1) and 120mg IV Q3W (Dose level -1) Nivolumab: 360mg IV Q3W

DRUG

Sacituzumab Govitecan (SG)

10 mg/kg IV D1 \& D8 every 21-day cycles (Dose level 1); 7.5 mg/kg IV D1 \& D8 every 21-day cycles (Dose level -1); 5 mg/kg IV D1 \& D8 every 21-day cycles 21-day cycles (Dose level -2)

DRUG

Nivolumab

360mg IV Q3W

Trial Locations (1)

06510

Yale University, New Haven